同仁堂國藥(03613.HK)獲董事增持16.2萬股股份
格隆匯 9 月 14日丨同仁堂國藥(03613.HK)發佈公告,董事會獲董事會主席兼執行董事丁永玲、首席執行官兼執行董事張煥平及首席運營官兼執行董事林曼告知,2020年9月8日至9月11日期間,丁永玲於市場上增持共4.2萬股股份,總代價約為35.5萬港元(平均價格約為每股8.45港元);張煥平於市場上增持共10萬股股份,總代價約為83.4萬港元(平均價格約為每股股份8.34港元);及林曼於市場上增持2萬股股份,總代價約為17.08萬港元(平均價格約為每股股份8.54港元)。
於該公告日期,增持股份後丁永玲持有公司合共41萬股股份,佔公司已發行股份約0.049%;張煥平持有公司合共10萬股股份,佔公司已發行股份約0.012%;林曼持有公司合共29萬股股份,佔公司已發行股份約0.035%。增持股份充分體現丁永玲、張煥平及林曼對公司整體發展前景及增長潛力的信心。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.